Share on StockTwits
 

Alexion Pharmaceuticals (NASDAQ:ALXN) EVP Stephen P. Squinto sold 7,055 shares of the company’s stock on the open market in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $158.04, for a total transaction of $1,114,972.20. Following the transaction, the executive vice president now directly owns 101,308 shares in the company, valued at approximately $16,010,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on ALXN. Analysts at Deutsche Bank raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $205.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $189.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, February 4th. They now have a $170.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $159.61.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 3.96% on Monday, hitting $170.11. 2,359,160 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $171.09. The stock’s 50-day moving average is $140.5 and its 200-day moving average is $121.6. The company has a market cap of $33.415 billion and a price-to-earnings ratio of 128.84.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, January 30th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.87 EPS for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.